Graft Versus Host Disease Following HLA-Matched Sibling Donor Compared with Matched Related Donor for Hematopoietic Stem Cell Transplantation for the Treatment of Severe Combined Immunodeficiency Disease

[1]  S. Forman,et al.  Hematopoietic Cell Transplantation , 2015 .

[2]  A. Al-ghonaium,et al.  Primary Immunodeficiency Diseases in Saudi Arabia: a Tertiary Care Hospital Experience over a Period of Three Years (2010–2013) , 2015, Journal of Clinical Immunology.

[3]  S. Paczesny.  Graft-versus-host disease in children after hematopoietic cell transplantation: potential clinical utility of biomarkers , 2015 .

[4]  C. Dvorak,et al.  Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency , 2015, Current Pediatrics Reports.

[5]  L. Notarangelo,et al.  Immune deficiencies, infection, and systemic immune disordersComparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency , 2014 .

[6]  L. Notarangelo,et al.  Transplantation outcomes for severe combined immunodeficiency, 2000-2009. , 2014, The New England journal of medicine.

[7]  A. Gennery,et al.  Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency☆ , 2014, The Journal of allergy and clinical immunology.

[8]  L. Notarangelo,et al.  Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. , 2014, The Journal of allergy and clinical immunology.

[9]  L. Notarangelo,et al.  The Natural History of Children with Severe Combined Immunodeficiency: Baseline Features of the First Fifty Patients of the Primary Immune Deficiency Treatment Consortium Prospective Study 6901 , 2013, Journal of Clinical Immunology.

[10]  Y. Lokhnygina,et al.  Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. , 2009, The Journal of pediatrics.

[11]  N. Patel,et al.  Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb. , 2008, The Journal of allergy and clinical immunology.

[12]  Mansour M. Qurachi,et al.  Regional variations in the prevalence of consanguinity in Saudi Arabia. , 2007, Saudi medical journal.

[13]  K. Sullivan.  Graft‐vs.‐Host Disease , 2007 .

[14]  L. Notarangelo,et al.  Bone marrow transplantation for severe combined immune deficiency. , 2006, JAMA.

[15]  R. Buckley.  Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. , 2004, Annual review of immunology.

[16]  A. Fischer,et al.  Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99 , 2003, The Lancet.

[17]  H. Pabst,et al.  Bone marrow transplantation for T−B− severe combined immunodeficiency disease in Athabascan-speaking native Americans , 2001, Bone Marrow Transplantation.

[18]  J. Roberts,et al.  Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. , 1999, The New England journal of medicine.

[19]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[20]  C. Craddock,et al.  NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHD. , 2018, European journal of immunology.